Side by Side
Compare Peptides
Trying to decide between two peptides? These neutral, cited side-by-sides lay out benefits, side effects, and the actual research — no hype, every claim linked to its source.
Trying to decide between two peptides? These neutral, cited side-by-sides lay out benefits, side effects, and the actual research — no hype, every claim linked to its source.
The two most-discussed injury-recovery peptides — often stacked, frequently compared.
Systemic tissue repair vs targeted skin, hair, and collagen regeneration.
Systemic tissue-repair peptide vs the anti-inflammatory tripeptide — gut and injury contexts.
Two gut-research staples compared: the systemic tissue-repair peptide vs the body's own antimicrobial peptide.
Thymosin Alpha-1 vs TB-500: immune modulation vs tissue repair — two thymosin-family peptides with distinct mechanisms.
Thymosin Alpha-1 vs BPC-157: immune-system support vs systemic tissue repair.
The two leading GLP-1 metabolic peptides behind the weight-loss wave.
The current GLP-1 leader vs the emerging next-generation triple-agonist.
The established GLP-1 agonist vs the emerging triple-agonist for metabolic outcomes.
The two best-known GLP-1 agonists — the once-weekly compound vs the once-daily original — compared across approved uses and research depth.
The dual GIP/GLP-1 agonist vs a single-receptor GLP-1 — the newest metabolic research against the established daily option.
The GLP-1 behind the weight-loss wave vs the amylin analog studied for the same metabolic endpoints — two different pathways aimed at similar goals.
The GLP-1 agonist vs the body's original blood-sugar hormone — different mechanisms studied for overlapping metabolic outcomes.
The two once-weekly GLP-1 medicines — the compound behind the weight-loss wave vs the long-established once-weekly option — compared across approved uses and research depth.
The current GLP-1 leader vs the original incretin mimic that started the class — twice-daily and once-weekly exenatide against the modern standard.
The two first-generation GLP-1 agonists — the incretin-mimic original vs the once-daily that followed — head to head across diabetes and weight outcomes.
The long-acting amylin analog vs the leading GLP-1 — the two halves of the combination studied as the next weight-loss wave.
The two anabolic hormone cousins — structural relatives with different jobs, studied side by side in growth and metabolism research.
Two growth-hormone secretagogues often studied together — a GHRH analog vs a GHRP.
Two GHRH (growth-hormone-releasing-hormone) analogs: tesamorelin — researched for visceral-fat outcomes and the one with an approved use — vs cjc-1295, the widely-studied research analog for growth-hormone pulse amplification.
Two GHRH analogs: sermorelin, the classic GH-releasing therapy used in stimulation testing, vs cjc-1295, the longer-acting research analog studied for sustained GH elevation.
A GHRH analog and a ghrelin-mimetic aimed at the same growth-hormone pulse — commonly stacked, frequently compared.
Two GHRH analogs: sermorelin, the classic short-acting GH-releasing therapy, vs tesamorelin — the one with an approved use, studied for visceral-fat outcomes.
Two ghrelin-mimetic GHRPs: the selective one studied for clean growth-hormone pulses vs the older, stronger-appetite original.
The two workhorse GHRPs — studied side by side for growth-hormone release and the appetite difference that separates them.
The two anabolic bone-building agents — the established teriparatide vs the newer analog studied for denser bone, faster.
Two bone-directed hormones going opposite ways: the antiresorptive that slows bone loss vs the anabolic that builds it.
The parent water-retention hormone vs its selective synthetic analog — the same family narrowed to one effect.
The body's own hormone brake vs its long-acting synthetic analog — the pair behind suppression testing and excess-hormone research.
The muscle-growth brake and the protein studied to block it — the myostatin–follistatin axis as a head-to-head.
Two ways to drive the same reproductive hormone cascade: the upstream brain signal vs the GnRH it releases.
Two mitochondrial approaches to the same question: the exercise-mimic signal the cell makes itself vs the peptide built to protect the mitochondrion directly.
The two Russian nootropic peptides — one studied for focus and learning, the other for anxiety — constantly compared and often stacked.
Peptide nootropics compared: a synthetic ACTH-related peptide studied for focus and memory vs the brain-peptide complex studied in cognitive research.
Two melanocortin-receptor agonists studied for pigmentation and sexual-function endpoints.
Melanotan I vs Melanotan II — the original tanning peptides: one developed into an approved photoprotection therapy, the other the raw research compound.
Epitalon vs Mots-C: two longevity-focused peptides — telomerase activation vs mitochondrial optimization.
Two longevity-research staples: the telomere-studied tetrapeptide vs the cellular-energy coenzyme behind the NAD+ wave.
SS-31 vs BPC-157: mitochondrial protection vs broad tissue repair — different repair strategies compared.
Two mitochondrial-research approaches compared: replenishing cellular NAD+ vs the mitochondria-targeted peptide studied to protect energy production directly.
Sister nonapeptides from the same hormone family, studied for bonding, trust, stress, and social behavior — the classic contrast pair in social-neuroscience research.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.
